A 45-year-old woman with hypertriglyceridemia is considered for niacin therapy. She is a known diabetic managed adequately with sugars well under control. Why should niacin be used cautiously in this patient?

Explanation

## Correct Answer: A. It can cause hyperglycemia. Niacin (vitamin B₃) is a potent lipid-lowering agent that effectively reduces triglycerides and LDL cholesterol while raising HDL. However, it carries a critical metabolic adverse effect: **hyperglycemia**. The mechanism involves niacin's inhibition of lipolysis in adipose tissue through G-protein coupled receptor signaling, which paradoxically increases hepatic glucose production and impairs insulin secretion. In diabetic patients—especially those on tight glycemic control—this can destabilize blood sugar levels and necessitate upward titration of antidiabetic medications. Indian guidelines (RNTCP/diabetes management protocols) recommend baseline HbA1c assessment and close glucose monitoring when initiating niacin in diabetics. The risk is dose-dependent and more pronounced with immediate-release formulations; extended-release niacin carries lower risk but still requires vigilance. Given this patient's well-controlled diabetes, the potential for niacin-induced hyperglycemia to unmask or worsen glycemic control makes cautious use (with frequent monitoring and possible dose adjustment of antidiabetic agents) mandatory rather than contraindicated. ## Why the other options are wrong **B. It can cause scleroderma, which makes injecting insulin difficult** — This is factually incorrect. Niacin does not cause scleroderma (systemic sclerosis). While niacin can cause skin flushing and pruritus, these are transient and reversible. Scleroderma is an autoimmune connective tissue disorder unrelated to niacin therapy. This option conflates unrelated adverse effects and represents a knowledge trap. **C. It can increase the metabolism of oral hypoglycemic drugs** — This is incorrect. Niacin does not induce hepatic metabolism of oral antidiabetic agents (metformin, sulfonylureas, DPP-4 inhibitors, etc.). The concern with niacin is its direct hyperglycemic effect, not altered drug metabolism. This option misdirects attention toward a non-existent drug interaction rather than the true pharmacodynamic problem. **D. It can cause hypoglycemia** — This is the opposite of niacin's true effect. Niacin causes **hyperglycemia**, not hypoglycemia. This option represents a classic NBE trap: presenting the inverse of the correct answer to catch students who know niacin has glucose-related effects but misremember the direction. Hypoglycemia would be a concern with insulin or sulfonylureas, not niacin. ## High-Yield Facts - **Niacin-induced hyperglycemia** occurs via inhibition of lipolysis and reduced insulin secretion, requiring glucose monitoring in diabetic patients. - **Extended-release niacin** carries lower hyperglycemic risk than immediate-release formulations and is preferred in diabetics. - **Baseline HbA1c and fasting glucose** should be documented before niacin initiation in all patients with diabetes or prediabetes. - **Niacin's lipid profile benefit** (↓TG, ↓LDL, ↑HDL) must be weighed against hyperglycemic risk in Indian diabetic populations with dyslipidemia. - **Flushing** (prostaglandin-mediated) is the most common niacin adverse effect; aspirin premedication or extended-release formulation mitigates this. ## Mnemonics **NIACIN Glucose Effect** **N**iacin → **I**nhibits lipolysis → **A**dverse glucose effect → **C**aution in **I**nsulin-dependent patients → **N**eed monitoring. Remember: Niacin ↓ lipolysis → ↑ hepatic glucose production → hyperglycemia risk. **Niacin Adverse Effects (FLUSH)** **F**lushing (most common), **L**iver enzymes ↑, **U**ric acid ↑ (gout), **S**kin (pruritus), **H**yperglycemia. Hyperglycemia is the metabolic trap in diabetics. ## NBE Trap NBE pairs niacin with a diabetic patient and offers both hyperglycemia (correct) and hypoglycemia (inverse trap) to catch students who know niacin affects glucose but misremember the direction. The scleroderma option is a pure distractor with no mechanistic link to niacin. ## Clinical Pearl In Indian clinical practice, niacin is often considered for hypertriglyceridemic diabetics (common in metabolic syndrome), but the hyperglycemic risk often limits its use; statins + fibrates are preferred first-line. When niacin is used, extended-release formulation with close HbA1c monitoring every 4–6 weeks is standard practice in Indian diabetes clinics. _Reference: KD Tripathi Ch. 31 (Vitamins & Lipid-Lowering Drugs); Harrison Ch. 395 (Lipid Disorders)_